Advertisement

Picture Sino Biological Symposium Antibody Engineering Leipzig 650x100px
All > Germany >

Deals > Western Germany

Find below deals from the Western German Federal States of Hessen, Nordrhein-Westfalen, Rheinland-Pfalz and Saarland. Listed are news deals for this region as well as from organisations located there.

Total search results: 508 | Ordered by Date (descending)
1 2 3 4 5 6  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Insempra–Henkel: investment, 202405 financing round Series A totalling $20m incl new investor Henkel dx Ventures 2024-05-07
Cultimate Foods–b.value: investment, 202404 seed financing round totalling €2.3m incl co-investor b.value AG 2024-04-23
Cultimate Foods–High-Tech Gründerfonds: investment, 202404 seed financing round totalling €2.3m incl lead investor HTGF 2024-04-23
Prothea Technologies–North Rhine-Westphalia (govt): investment, 202404 financing round Series A totalling €12m incl co-investor NRW.BANK 2024-04-09
Merck (DE)–Caris Life Sciences: AI-based drug discovery, 202404– collab strategic up to $1.4b discovery of cancer targets for ADC RnD 2024-04-04
Perspix Biotech–BioCopy: investment, 20403 acquisition of Perspix Biotech GmbH by BioCopy AG + renamed to BioCopy Analytix GmbH 2024-03-20
Asgard Therapeutics–Boehringer: investment, 202403 financing round Series A totalling €30m incl existing + co-investor BIVF 2024-03-14
Tubulis–Germany (govt): investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor Coparion 2024-03-14
Tubulis–High-Tech Gründerfonds: investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor HTGF 2024-03-14
Boehringer–Sosei: GPR52 agonists, 202403– collab drug discovery + excl ww license option €25m upfront + €730m milestones plus tiered royalties 2024-03-11
Merck (DE)–C4 Therapeutics: protein degraders, 202403– license + collab $16m upfront + $740m milestones + royalties discovery of 2 protein degraders 2024-03-04
BRAIN Biotech–Putsch (Recaro): credit, 202402–202609 convertible bond €5m with MP Beteiligungs-GmbH at 6.52% p.a. 2024-02-29
Cyclize–High-Tech Gründerfonds: investment, 202402 seed financing round totalling €4.75m incl co-investor HTGF 2024-02-21
Rhineland-Palatinate (govt)–Axa: business park management, 202401– collab of Kadans Science Partner Deutschland + Technologiezentrum Mainz for biotech 2024-01-29
Disco Pharmaceuticals–AbbVie: investment, 202401 seed financing round totalling €20m incl co-investor AbbVie Ventures 2024-01-16
Disco Pharmaceuticals–Merck (DE): investment, 202401 seed financing round totalling €20m incl co-investor M Ventures 2024-01-16
Disco Pharmaceuticals–Panakés Partners: investment, 202401 seed financing round totalling €20m incl co-investor Panakés Partners 2024-01-16
Disco Pharmaceuticals–SEVERAL: investment, 202401 seed financing round €20m led by Sofinnova Partners 2024-01-16
Disco Pharmaceuticals–Sofinnova: investment, 202401 seed financing round totalling €20m incl lead investor Sofinnova Partners 2024-01-16
BioNTech–WuXi PharmaTech: drug discovery services, 202401– supply discovery of MAb candidates $20m upfront + milestones + royalties by WuXi Biologics 2024-01-11
BioNTech–JPMorgan Chase: investor conference, 202401 supply service BioNTech presents at JP Morgan Healthcare Conference 2024 2024-01-09
Merck (DE)–Inspirna: ompenaclid, 202401– license excl ww ex-US $45m upfront + milestones + royalties 2024-01-04
Paion–Humanwell Healthcare: investment, 202312 acquisition of essential business operation of insolvent Paion AG + Paion Deutschland GmbH 2023-12-22
Odyssey Therapeutics–BlackMars Capital: investment, 202312 financing round Series C totalling $101m incl co-investor BlackMars Capital 2023-12-05
WMT AG–FS Life Science Investment: investment, 202311 investment by FS Investment in WMT as part of current bridge financing 2023-11-28
WMT AG–High-Tech Gründerfonds: investment, 202311 existent HTGF is existing investor in WMT 2023-11-28
T3 Pharmaceuticals–Boehringer: investment, 202311 acquisition of T3 Pharma for up to CHF450m by Boehringer Ingelheim 2023-11-22
RED Horticulture–ECBF: investment, 202311 financing round Series A totalling €17m incl new + lead investor ECBF 2023-11-21
Merck (DE)–Hengrui: cancer drugs, 202310– strategic alliance €160m upfront + total up to €1.4b license HRS-1167 + option SHR-A1904 ww excl China 2023-10-30
FarmInsect–High-Tech Gründerfonds: investment, 202310 financing round Series A totalling €8m incl existing + co-investor HTGF 2023-10-23
BioNTech–MediLink Therapeutics: antibody-drug conjugates, 202310– collab + ww license excl China $70m upfront + $>1b milestones for anti-HER3 ADC 2023-10-12
Japan Tobacco–Max Planck: drug discovery, 202310– collab up to 7 years with Lead Discovery Center + its academic network 2023-10-11
Kranus Health–High-Tech Gründerfonds: investment, 202310 financing round Series A expansion totalling approx $8.5m incl existing + co-investor HTGF 2023-10-02
AexeRNA Therapeutics–BioNTech: investment, 202310 acquisition €na of AexeRNA by BioNTech 2023-10-01
Mainz Biomed–Cantor Fitzgerald: investor conference, 202309 supply service Mainz Biomed presents at CF Global Healthcare Conference 2023 in NY 2023-09-28
Traceless Materials–b.value: investment, 202309 financing round Series A totalling €36.6m incl existing + co-investor b.value 2023-09-25
Traceless Materials–High-Tech Gründerfonds: investment, 202309 financing round Series A totalling €36.6m incl existing + co-investor HTGF 2023-09-25
Mainz Biomed–MC Services: public relations, 202309 service existent by MC Services 2023-09-20
Merck (DE)–BenevolentAI: AI-based drug discovery, 202309– strategic collab up to $594m plus royalties incl low 2-digit-$m upfront 2023-09-20
Merck (DE)–Exscientia: AI-based drug discovery, 202309– collab $20m upfront + $674m milestones plus royalties 2023-09-20
Oncgnostics–High-Tech Gründerfonds: investment, 202309 financing round totalling €7-digit incl existing + co-investor HTGF 2023-09-05
AbbVie–Temedica: digital patient companion app, 202308 collab launch of companion app Tami for patients with chronic IBD in Germany 2023-08-02
Bind-X–High-Tech Gründerfonds: investment, 202308 existing investor HTGF 2023-08-01
BioNTech–Duality Biologics: antibody-drug conjugates, 202308– license excl ww excl China? to develop + manufacture + commercialise DB-1305 2023-08-01
Crescendo Biologics–BioNTech: investment, 202307 financing round totalling $32m incl existing investor BioNTech 2023-07-24
CrystalsFirst–NexMR: fragment-based drug discovery, 202307– collab combining crystallography technology with NRM for drug discovery 2023-07-24
TVM–MC Services: public relations, 202307 service existent by MC Services 2023-07-20
BioNTech–Biotheus: antibody cancer drug, 202307– strategic research collab + ww excl option + license agreement 2023-07-19
BioNTech–Biotheus: antibody cancer drug, 202311– collab + license ww excl ex-Greater China for PM8002 $55m upfront + >$1b milestones + royalties 2023-07-19
Vertama–High-Tech Gründerfonds: investment, 202307 seed financing round totalling 7-digit € incl lead investor HTGF 2023-07-12
BioNTech–Doer Biologics: biopharmaceuticals, 202308– license ww to use Doer Bio discovery to develop + market biotherapeutics against one target 2023-07-10
Zoetis–Numaferm: peptide technology, 202307– license + collab €na using peptein technology for RnD of veterinary therapeutics 2023-07-06
Emergence Therapeutics–Lilly: investment, 202306 acquisition 100% of Emergence Therapeutics AG by Eli Lilly 2023-06-29
DNTox–SEVERAL: investment, 202306 seed financing round €1.4m led by HTGF 2023-06-14
Prosion–10xDNA: investment, 202205 existent 7-figure seed investment by 10xDNA 2023-05-23
Smartbax–Boehringer: investment, 202305 seed financing round totalling €1.2m incl existing investor BIVF 2023-05-23
Smartbax–High-Tech Gründerfonds: investment, 202305 seed financing round totalling €1.2m incl new investor HTGF 2023-05-23
Dualyx–High-Tech Gründerfonds: investment, 202305 financing round Series A totalling €40m incl existing + co-investor HTGF 2023-05-15
Nia Health–High-Tech Gründerfonds: investment, 202305 seed financing round totalling €3.5m incl lead investor HTGF 2023-05-15
Repare Therapeutics–Vivlion: gene editing, 202305– supply of PRICSR CRISPR gRNA libraries for synthetic lethal screening by Vivlion 2023-05-11
DiogenX–Boehringer: investment, 202305 financing round Series A totalling €27.5m incl existing + co-lead investor Boehringer Ingelheim Venture Fund 2023-05-10
PolyPeptide–Numaferm: peptide synthesis, 202305– collab €na Preferred Partner Collaboration Agreement for peptide development + production 2023-05-09
Clickmer Systems–APIS Assay Technologies: investment, 202204 acquisition of Clickmer Systems for single-digit €m by APIS Assay Technologies Ltd 2023-04-25
BioNTech–Duality Biologics: antibody-drug conjugates, 202304– license excl ww excl China for DB-1303 + DB-131 $170m upfront + >$1.5b milestones + roy 2023-04-03
Deepc–Bertelsmann: investment, 202303 financing round Series A totalling €12m incl new + co-investor Bertelsmann Investments 2023-03-28
Mbiomics–High-Tech Gründerfonds: investment, 202303 financing round Series A first closing totalling €13m incl co-investor HTGF 2023-03-23
BioNTech–OncoC4: antibody cancer drug, 202303– license ww excl + co-developm incl $200m upfront of anti-CTLA-4 mAb ONC-392 2023-03-20
Lino Biotech–Miltenyi Biotec: investment, 202303 acquisition €na of Lino Biotech by Miltenyi Biotec 2023-03-16
Prosion–Collaborative Drug Discovery: data management software, 202302– supply service Prosion to use CDD Vault to host its RnD data 2023-02-23
AMSilk–BRAIN Biotech: biomaterials, 202302– strategic collaboration development of high-performance bio-based protein fibers 2023-02-08
BrainRepair–OTHER: investment, 202302 investment €50m for 20% of shares of BrainRepair UG by London-based group 2023-02-08
Refined Laser Systems–Apex Ventures: investment, 202301 seed financing round totalling €2.7m incl co-lead investor Apex Medical Fund 2023-01-26
Refined Laser Systems–High-Tech Gründerfonds: investment, 202301 seed financing round totalling €2.7m incl co-lead investor HTGF 2023-01-26
Refined Laser Systems–North Rhine-Westphalia (govt): investment, 202301 seed financing round totalling €2.7m incl co-investor NRW.Bank 2023-01-26
Refined Laser Systems–Onsight Ventures: investment, 202301 seed financing round totalling €2.7m incl co-investor Onsight Ventures 2023-01-26
Refined Laser Systems–Papst: investment, 202301 seed financing round totalling €2.7m incl co-investor Papst Venture Capital 2023-01-26
Refined Laser Systems–PERSON: investment, 202301 seed financing round totalling €2.7m incl private investors T Merk + HM Hauser + W Falkenstein 2023-01-26
Refined Laser Systems–SEVERAL: investment, 202301 seed financing round €2.7m led by HTGF + Apex Ventures 2023-01-26
Blackford Analysis–Bayer: investment, 202301–202302 acquisition by Bayer 2023-01-18
Bayer–Alphabet: cloud computing services, 202301– collab using Google Cloud TPUs for quantum chemitry calculations in drug discovery 2023-01-11
BioNTech–JPMorgan Chase: investor conference, 202301 supply service BioNTech presents at JP Morgan Healthcare Conference 2023 2023-01-10
Boehringer–Minapharm: rec protein production technology, 202301– collab non-excl €na of ProBioGen + Boehringer on DirectedLuck transposase technology 2023-01-10
InstaDeep–BioNTech: investment, 202301–202307 acquisition of all remaining InstaDeep shares for £362m upfront in cash + shares plus £200m milestones 2023-01-10
Boehringer–3T Biosciences: cancer immunotherapies, 202301– strategic collab + license agreem RnD of cancer therapies using 3T-TRACE discovery platform 2023-01-09
Selfapy–High-Tech Gründerfonds: investment, 202212 financing round totalling €7m incl existing + co-investor HTGF 2022-12-23
Selfapy–Medice: investment, 202212 financing round totalling €7m incl new + lead investor Medice Arzneimittel 2022-12-23
Merck (DE)–Mersana: ADC technology, 202212– collab €30m upfront + $800m milestones + royalties using Immunosynthen platform for STING-agonist ADCs 2022-12-22
Boehringer–Click Therapeutics: digital therapeutics, 202212– collab expansion to develop 2nd DTx for schizophrenia up to $460m + royalties 2022-12-19
Erbi Biosytems–Merck (DE): investment, 202212 acquisition €na of Erbi Biosystems by Merck 2022-12-01
BioNTech–Ryvu Therapeutics: small molecule immuno modulators, 202211– collab + license €20m upfront + research funding + milestones + royalties 2022-11-30
Ryvu Therapeutics–BioNTech: investment, 202212 public offering totalling PLN250.3m incl PLN94m (€20m) from lead investor BioNTech related to collab 2022-11-30
Catalym–Germany (govt): investment, 202211 financing round Series C totalling €50m incl existing + co-investor Coparion 2022-11-22
FundaMental Pharma–Germany (govt): investment, 202211 seed financing round totalling €10m incl co-investor Coparion 2022-11-17
FundaMental Pharma–High-Tech Gründerfonds: investment, 202211 seed financing round totalling €10m incl co-investor HTGF (=202106 or not??) 2022-11-17
Targenomix–Bayer: investment, 202211 acquisition 100% of former partner Targenomix by Bayer CropScience to continue as standalone subsidiary 2022-11-10
Ayoxxa–NONE: investment, 202211– filed for bankruptcy 2022-11-04
European Spatial Biology Center–Resolve Biosciences: Molecular Cartography technology, 202210 supply to ESBC existent 2022-10-24
Helmholtz–Resolve Biosciences: Molecular Cartography technology, 202210 supply to DKFZ existent as one of first customers 2022-10-24
Resolve Biosciences–Alafi Capital: investment, 202210 financing round Series B totalling $71m incl existing + co-investor Alafi Capital 2022-10-24
Resolve Biosciences–EDBI: investment, 202210 financing round Series B totalling $71m incl co-investor EDBI 2022-10-24
1 2 3 4 5 6  next pagenext page



Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Berlin Partner Top News Captain T Cell Therapies 650x300px

» top